FL-EIGHT-SLEEP
27.7.2022 17:02:04 CEST | Business Wire | Press release
Today, Eight Sleep , the world’s first sleep fitness company, introduced Pod 3, a new version of their award-winning sleep technology. Pod 3 features a new quad-core CPU as well as upgrades to its sensor system, powering more accurate biometric and health tracking with twice the number of sensors and 4000x greater resolution. The new sensor system achieves 99% heart rate sensing accuracy compared to clinical reference¹. Furthermore, clinical data have shown that the technology behind Pod 3 can improve sleep quality index by up to 32%², increase deep sleep by up to 34%³, and increase heart rate variability (HRV) by up to 19%³. The release of Pod 3 is part of Eight Sleep’s journey to transform an ordinary bed into an advanced health platform that fuels both recovery and performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220727005241/en/
“From the start, we set out to create the best systems in the world to power sleep optimization, and with the launch of Pod 3 we are taking a giant leap forward,” said Matteo Franceschetti, Co-founder and CEO of Eight Sleep . “Three years after the launch of the original Pod, it is rewarding to see how our innovations are improving people’s lives, with clinically validated results that prove better recovery night after night.”
Thermoregulating technology that improves sleep quality and increases HRV
The Pod’s Active Grid layer, which wraps around any mattress like a cover, continues to provide dynamic heating and cooling between 55℉ and 110℉ on each side of the bed. This allows members to maintain a comfortable temperature range during sleep, which has been clinically demonstrated to improve sleep quality index, time spent in deep sleep, as well as heart rate variability:
- Increase deep sleep by up to 34%³: After just one week of sleeping on the Pod, individuals experienced a 10% average increase and a 34% maximum increase in deep sleep. Individuals that initially had below-average deep sleep duration had the largest increase in deep sleep after using the Pod. As deep sleep is crucial for several key bodily processes, including learning and memory, recovery from exercise, immunity, and metabolism, sleeping on the Pod can be highly beneficial for people struggling to get optimal amounts of deep sleep each night.
- Improve clinical sleep quality by up to 32%²: The Pod has been shown to improve the sleep quality of individuals by up to 32% using standard clinical measurements. The average Pod user also experiences 34% higher daytime energy scores, 23% fewer sleep interruptions, and 44% faster sleep onset, compared to their baseline before sleeping on the Pod.
- Increase heart rate variability (HRV) by up to 19%³: After one week of sleeping on the Pod, users show an average increase in their HRV by 6%. For one in three Eight Sleep users, HRV increases by at least 10%, and one in four users sees an HRV increase of at least 15%. Importantly, individuals with a below-average HRV experienced the largest increases in HRV after sleeping on the Pod with an average 9% increase and a 19% maximum increase. An increase in HRV indicates improved recovery, cardiovascular health, and cognitive performance.
While still maintaining the award-winning features of the Pod 2 Pro, the new Pod 3 includes enhanced technology and an improved user experience with the following enhancements:
A new quad-core CPU to increase the Pod’s computing power
A powerful new quad-core CPU significantly increases computing power in Pod 3 that allows for double the amount of sensors for tracking key biometrics such as heart rate, HRV, respiratory rate, sleep stages, and more. With a more robust hardware system, the Pod can now locally process more complex data and algorithms, critical for biometrics tracking during sleep. Additionally, the new hardware allows for future deep-learning-powered features to be pushed to users via frequent cloud updates.
Invisible Sensing design featuring twice the number of sensors and 4000x greater resolution in sleep and health tracking
Pod 3 includes a new Invisible Sensing design of its sensor pack to maximize comfort while providing more accurate measurements with double the amount of sensors and 4000x greater sensor resolution. Building on the previous generation’s excellent biometric accuracy³, Pod 3’s dual sensors enable a further 20% improvement in heart rate variability accuracy, as well as a maximum error of heart rate of less than 1 beat per minute compared to clinical reference.
Dual-band Wi-Fi chip with 5GHz compatibility for a wider connectivity range
A new, dual-band Wi-Fi chip in the Hub extends compatibility from 2.4GHz networks to 5GHz networks, as well as improves support for mesh networks. This update increases connection speed and Wi-Fi stability, allowing the Pod to find the best balance between long-range and high bandwidth connectivity, regardless of the layout of the user’s home.
The Eight Sleep app provides health insights and more with 8+
The powerful features of Pod 3 are managed from the Eight Sleep app which serves as a one-stop dashboard to view health and sleep metrics, adjust sleep preferences, and manage temperature settings. With an optional 8+ membership users can take their sleep to the next level. 8+ unlocks the full intelligence of the product, built utilizing insights from more than 90 million hours of sleep data. The features in the Eight Sleep App include:
- Temperature Autopilot: Autopilot uses AI to adjust the user’s sleeping temperature in real-time based on their sleep history, past temperature preferences, bedroom temperature, local weather, and user feedback.
- Health and Sleep Reports: A Sleep Fitness Report is available daily, and includes key health metrics such as heart rate, heart rate variability, sleep time, deep sleep, REM sleep, and respiratory rate.
- Connection to third-party wearables: Users can link their favorite third-party fitness devices with the Eight Sleep app to understand how their daytime activities affect their sleep. Devices supported include Peloton, Oura, Garmin, Apple Health, Google Health, Fitbit, Trainingpeaks, Polar, and Zwift.
- Behavioral Insights: 8+ offers powerful sleep and health insights, based on more than 90 million hours of sleep data, and creates personalized recommendations for each user with actionable suggestions to promote positive behavior change.
- Content designed to help you sleep: 8+ members get access to a growing library of content including guided breathing, yoga, meditations, and more designed to help users fall asleep faster and wake up energized.
“Pod 3 is the next step for Eight Sleep to push the boundaries of what is possible for sleep technology that not only monitors your health, but also improves it. The new sensing and computing hardware in Pod 3 allows for more complex biometric algorithms to be deployed, giving our members the best and most innovative features for restorative and preventative health. This was all achieved while making the Pod even more comfortable with a new Invisible Sensing design,” says Dr. David He, Vice President of Research and Development at Eight Sleep .
Available today
The Eight Sleep Pod 3 is available to purchase online today. Pricing starts at $2,095 for a Full size, $2,195 for Queen, $2,395 for King and California King Pod 3 Cover. Priority upgrades are available for existing Eight Sleep members. Eight Sleep upholds its customer satisfaction, offering up to a 100-night trial and free returns. For more information about Pod 3, check out the video here and to purchase the Pod, visit eightsleep.com .
About Eight Sleep
Eight Sleep is the world's first sleep fitness company with a mission to fuel human potential through optimal sleep. Their hardware, software, and AI technologies power pro athletes and everyday high performers around the globe, including snowboarding sensation and Olympic Gold-Medalist Red Gerard, the world’s fittest man 2021 CrossFit Games Winner Justin Medeiros, and the 8X Formula One Champions, Mercedes-AMG PETRONAS Formula One Team. Eight Sleep was named one of Fast Company's Most Innovative Companies in 2019 & 2022. The company was also recognized two years in a row by TIME's “Best Inventions of the Year.” Eight Sleep is available for purchase in North America (the United States and Canada) and throughout the United Kingdom, Europe (Belgium, France, Germany, Italy, Netherlands, and Spain) and Australia via eightsleep.com.
References
- Eight Sleep Pod’s Heart Rate and Heart Rate Variability Accuracy
- Eight Sleep Pod Leads to Improved Sleep Quality
- HRV, HR & Deep Sleep Improvement
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005241/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
